← Leaderboards
Yadong Huang
J. David Gladstone Institutes
$44,833,692
Attributed
$56,933,098
Total exposure
24
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $14.4M · FY2006–25$20M$15M$10M$5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$80,364,486 · 25
By mechanism
R01$31,759,504 · 13
P01$31,598,551 · 6
RF1$15,881,535 · 5
P50$1,124,896 · 1
Top collaborators
- Lennart Mucke8 shared
- Fen-Biao Gao5 shared
- Bruce L Miller5 shared
- Yanhong Shi5 shared
- Marina Sirota5 shared
- Misha Yuri Zilberter3 shared
- Konstantinos Arfanakis1 shared
- Mathew Mark Blurton-Jones1 shared
Most similar at J. David Gladstone Institutes
Same institution · by research overlap
- Erik D Roberson$10,777,149
- Steven M Finkbeiner$50,309,699
- Stephanie Regina Miller$451,890
- Jorge J Palop$21,103,782
- Tony Wyss-Coray$32,197,912
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
- Denis A Evans · Rush University Medical Center$28,117,218
Research focus
Alzheimer&AposS DiseaseApolipoprotein EPathogenesisNeuronsApolipoprotein E-4Mouse ModelGenesMolecularPathway InteractionsCellsProtein IsoformsCell TypeInsightGenetic Risk FactorTau ProteinsS Disease RiskPreventAge Of OnsetApolipoprotein E-3Neurodegenerative DisordersDrug DevelopmentGenotypeMediating
Grant awards (83)
Decoding the Multifactorial Etiology of Neural Network Dysfunction in Alzheimer's Disease$4,564,091
P01 · FY2025 · AG
Develop AD Connectivity Maps with Human iPSC-Derived Brain Cells and their Use$922,930
R01 · FY2025 · AG · contact PI
Study Alzheimer's Disease Protective APOE Variants$922,536
R01 · FY2025 · AG · contact PI
Project 1: Differential Roles of ApoE Isoforms in Neural Network Dysfunction of Alzheimer's Disease$916,822
P01 · FY2025 · AG · contact PI
Study Susceptibility and Resistance to ApoE4 in Alzheimer's Disease$861,422
R01 · FY2025 · AG · contact PI
Targeting Nell2 and GABAergic Dysfunction to Mitigate APOE4-Driven Pathogenesis in Alzheimer's Disease$804,450
R01 · FY2025 · AG
Neuronal ApoE Drives Selective Neurodegeneration in Alzheimer's Disease$800,972
R01 · FY2025 · AG · contact PI
Vascular-immune mechanisms of cerebral amyloid angiopathy and Alzheimer's pathology$5,423,836
RF1 · FY2024 · NS
Decoding the Multifactorial Etiology of Neural Network Dysfunction in Alzheimer's Disease$4,657,774
P01 · FY2024 · AG
Project 1: Differential Roles of ApoE Isoforms in Neural Network Dysfunction of Alzheimer's Disease$942,704
P01 · FY2024 · AG · contact PI
Develop AD Connectivity Maps with Human iPSC-Derived Brain Cells and their Use$941,764
R01 · FY2024 · AG · contact PI
Study Alzheimer's Disease Protective APOE Variants$941,364
R01 · FY2024 · AG · contact PI
Neuronal ApoE Drives Selective Neurodegeneration in Alzheimer's Disease$817,317
R01 · FY2024 · AG · contact PI
Study the Protective Roles of ApoE2 in Alzheimer's Disease Using Reprogrammed Isogenic Cells$724,286
R01 · FY2024 · AG · contact PI
Decoding the Multifactorial Etiology of Neural Network Dysfunction in Alzheimer's Disease$4,657,222
P01 · FY2023 · AG
Project 1: Differential Roles of ApoE Isoforms in Neural Network Dysfunction of Alzheimer's Disease$942,704
P01 · FY2023 · AG · contact PI
Develop AD Connectivity Maps with Human iPSC-Derived Brain Cells and their Use$941,764
R01 · FY2023 · AG · contact PI
Neuronal ApoE Drives Selective Neurodegeneration in Alzheimer's Disease$817,317
R01 · FY2023 · AG · contact PI
Study the Protective Roles of ApoE2 in Alzheimer's Disease Using Reprogrammed Isogenic Cells$724,286
R01 · FY2023 · AG · contact PI
Decoding the Multifactorial Etiology of Neural Network Dysfunction in Alzheimer's Disease$65,507
P01 · FY2023 · AG
Decoding the Multifactorial Etiology of Neural Network Dysfunction in Alzheimer's Disease$4,611,009
P01 · FY2022 · AG
Study Susceptibility and Resistance to ApoE4 in Alzheimer's Disease$2,637,009
RF1 · FY2022 · AG · contact PI
Project 1: Differential Roles of ApoE Isoforms in Neural Network Dysfunction of Alzheimer's Disease$942,704
P01 · FY2022 · AG · contact PI
Develop AD Connectivity Maps with Human iPSC-Derived Brain Cells and their Use$941,764
R01 · FY2022 · AG · contact PI
Neuronal ApoE Drives Selective Neurodegeneration in Alzheimer's Disease$817,317
R01 · FY2022 · AG · contact PI
Study the Protective Roles of ApoE2 in Alzheimer's Disease Using Reprogrammed Isogenic Cells$724,286
R01 · FY2022 · AG · contact PI
Decoding the Multifactorial Etiology of Neural Network Dysfunction in Alzheimer's Disease$157,218
P01 · FY2022 · AG
Decoding the Multifactorial Etiology of Neural Network Dysfunction in Alzheimer's Disease$91,710
P01 · FY2022 · AG
Decoding the Multifactorial Etiology of Neural Network Dysfunction in Alzheimer's Disease$4,626,857
P01 · FY2021 · AG
Project 1: Differential Roles of ApoE Isoforms in Neural Network Dysfunction of Alzheimer's Disease$942,704
P01 · FY2021 · AG · contact PI
ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease$853,475
R01 · FY2021 · AG · contact PI
Neuronal ApoE Drives Selective Neurodegeneration in Alzheimer's Disease$817,317
R01 · FY2021 · AG · contact PI
Study the Protective Roles of ApoE2 in Alzheimer's Disease Using Reprogrammed Isogenic Cells$724,286
R01 · FY2021 · AG · contact PI
Study ApoE4's Effects on Hippocampal Network Activity in Alzheimer's Disease$711,495
R01 · FY2021 · AG · contact PI
Modeling Alzheimerâs disease using directly reprogrammed isogenic neural cells$445,140
R01 · FY2021 · AG
ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease$853,475
R01 · FY2020 · AG · contact PI
Study ApoE4's Effects on Hippocampal Network Activity in Alzheimer's Disease$711,495
R01 · FY2020 · AG · contact PI
Study the Protective Roles of ApoE2 in Alzheimer's Disease Using Reprogrammed Isogenic Cells$699,716
R01 · FY2020 · AG · contact PI
Modeling Alzheimerâs disease using directly reprogrammed isogenic neural cells$445,140
R01 · FY2020 · AG
ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease$853,475
R01 · FY2019 · AG · contact PI
Study ApoE4's Effects on Hippocampal Network Activity in Alzheimer's Disease$711,495
R01 · FY2019 · AG · contact PI
Modeling Alzheimerâs disease using directly reprogrammed isogenic neural cells$445,140
R01 · FY2019 · AG
Apolipoprotein E in Alzheimer's Disease: Molecular Mechanism$388,065
R01 · FY2019 · AG · contact PI
ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease$853,475
R01 · FY2018 · AG · contact PI
Study ApoE4's Effects on Hippocampal Network Activity in Alzheimer's Disease$711,495
R01 · FY2018 · AG · contact PI
Modeling Alzheimerâs disease using directly reprogrammed isogenic neural cells$445,140
R01 · FY2018 · AG
Apolipoprotein E in Alzheimer's Disease: Molecular Mechanism$388,065
R01 · FY2018 · AG · contact PI
Project 3: Using Human iPS Cells to Study the Pathogenesis of AD and FTD$217,189
P50 · FY2018 · AG · contact PI
Roles of ApoE4 in Brain Aging and Alzheimer's Disease$3,284,440
RF1 · FY2017 · AG · contact PI
ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease$875,721
R01 · FY2017 · AG · contact PI
Study ApoE4's Effects on Hippocampal Network Activity in Alzheimer's Disease$726,495
R01 · FY2017 · AG · contact PI
Modeling Alzheimerâs disease using directly reprogrammed isogenic neural cells$463,390
R01 · FY2017 · AG
Apolipoprotein E in Alzheimer's Disease: Molecular Mechanism$388,065
R01 · FY2017 · AG · contact PI
Project 3: Using Human iPS Cells to Study the Pathogenesis of AD and FTD$213,001
P50 · FY2017 · AG · contact PI
Frontotemporal Dementia Induced Pluripotent Stem Cell Consortium$706,012
R01 · FY2016 · NS · contact PI
Apolipoprotein E in Alzheimer's Disease: Molecular Mechanism$388,065
R01 · FY2016 · AG · contact PI
Project 3: Using Human iPS Cells to Study the Pathogenesis of AD and FTD$229,200
P50 · FY2016 · AG · contact PI
Frontotemporal Dementia Induced Pluripotent Stem Cell Consortium$708,880
R01 · FY2015 · NS · contact PI
Apolipoprotein E in Alzheimer's Disease: Molecular Mechanism$388,065
R01 · FY2015 · AG · contact PI
Frontotemporal Dementia Induced Pluripotent Stem Cell Consortium$259,844
R01 · FY2015 · NS · contact PI
Project 3: Using Human iPS Cells to Study the Pathogenesis of AD and FTD$221,870
P50 · FY2015 · AG · contact PI
Studying Alzheimer's Disease Using Human iPS Cells$2,387,500
RF1 · FY2014 · AG · contact PI
Optogenetic Study of ApoE4-Related Alzheimers Disease$2,148,750
RF1 · FY2014 · AG · contact PI
Frontotemporal Dementia Induced Pluripotent Stem Cell Consortium$701,150
R01 · FY2014 · NS · contact PI
Project 3: Using Human iPS Cells to Study the Pathogenesis of AD and FTD$243,636
P50 · FY2014 · AG · contact PI
Frontotemporal Dementia Induced Pluripotent Stem Cell Consortium$751,616
R01 · FY2013 · NS · contact PI
Apolipoprotein E in Alzheimer's Disease: Cellular Mechanisms$270,632
P01 · FY2012 · AG · contact PI
Tissue Culture Core$140,728
P01 · FY2012 · AG · contact PI
Apolipoprotein E in Alzheimer's Disease: Cellular Mechanisms$545,201
P01 · FY2011 · AG · contact PI
Tissue Culture Core$283,501
P01 · FY2011 · AG · contact PI
Apolipoprotein E in Alzheimer's Disease: Cellular Mechanisms$421,255
P01 · FY2010 · AG · contact PI
Tissue Culture Core$219,051
P01 · FY2010 · AG · contact PI
Apolipoprotein E in Alzheimer's Disease: Cellular Mechanisms$403,297
P01 · FY2009 · AG · contact PI
Tissue Culture Core$209,712
P01 · FY2009 · AG · contact PI
Apolipoprotein E in Alzheimer's Disease: Cellular Mechanisms$391,550
P01 · FY2008 · AG · contact PI
Tissue Culture Core$203,606
P01 · FY2008 · AG · contact PI
CORE--TISSUE CULTURE$235,402
P01 · FY2007 · AG · contact PI
CORE--TISSUE CULTURE$155,590
P01 · FY2006 · AG · contact PI
Regulation of Apolipoprotein Synthesis$400,500
R01 · FY2004 · HL
APOE EXPRESSION LEVEL MODULATES VLDL METABOLISM$306,834
R01 · FY2003 · HL
APOE EXPRESSION LEVEL MODULATES VLDL METABOLISM$320,306
R01 · FY2002 · HL
APOE EXPRESSION LEVEL MODULATES VLDL METABOLISM$310,977
R01 · FY2001 · HL
APOE EXPRESSION LEVEL MODULATES VLDL METABOLISM$301,920
R01 · FY2000 · HL